SYNAIRGEN PLC

Regulatory Filings • Apr 30, 2020

National Storage Mechanism | Additional information

RNS Number : 5139L

Synairgen plc

30 April 2020

Press release

Synairgen plc

('Synairgen' or the 'Company')

Approval received to extend SG016 clinical study of SNG001 in COVID-19 to initiate patients in the home environment

Southampton, UK - 30 April 2020: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, announces that it has received approvals to extend the SG016 trial to patients with SARS-CoV-2 in the home environment. The objective is to initiate dosing with SNG001 (or placebo) earlier in the infection cycle, and before severe lower respiratory tract symptoms have developed. In due course, details of the design, implementation and timing of this novel study will be disclosed more fully. 

The treatment of patients in the hospital setting in the SG016 study is progressing well, with more than 75 patients out of the target 100 now dosed with Synairgen's wholly-owned drug SNG001 or placebo. Results from this part of the study are still expected in June 2020. 

For further enquiries, please contact:

Synairgen plc

Richard Marsden, Chief Executive Officer

John Ward, Finance Director

Tel: + 44 (0) 23 8051 2800

finnCap

Geoff Nash, Kate Bannatyne, Charlie Beeson (Corporate Finance)

Alice Lane, Manasa Patil (ECM)

Tel: + 44 (0) 20 7220 0500

Consilium Strategic Communications (Financial Media and Investor

Relations)

Mary-Jane Elliott, Sue Stuart, Olivia Manser

synairgen@consilium-comms.com

Tel: +44 (0) 20 3709 5700

Notes for Editors

About Synairgen 

Synairgen is a respiratory drug discovery and development company founded by University of Southampton Professors Stephen Holgate, Donna Davies and Ratko Djukanovic. The business, focused primarily on lung viral defence in asthma and COPD, uses its differentiating human biology BioBank platform and world-renowned international academic KOL network to discover and develop novel therapies for respiratory disease.  

Synairgen is quoted on AIM (LSE: SNG). For more information about Synairgen, please see www.synairgen.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

MSCURRARRSUSOAR